Sign Up Today and Learn More About SOMAÍ Pharmaceuticals Stock

Invest in or calculate the value of your shares in SOMAÍ Pharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

SOMAÍ Pharmaceuticals Stock

SOMAÍ Pharmaceuticals is a pharmaceutical and biotech company that specializes in cannabinoid-containing pharmaceutical medicines.

About SOMAÍ Pharmaceuticals Stock



At SOMAÍ, we are on a journey to build a leading global brand with the most robust portfolio of innovative cannabis-based therapeutics. We envision a world where people live healthy lifestyles empowered by natural cannabis medicine. Our company is dedicated to formulating innovative cannabis-based products to ensure a healthy and comfortable life. For that, we create a wide variety of medications for chronic patients and different conditions. We aim to design calm and satisfactory experience of administering, prescribing and purchasing cannabis-based medicine. SOMAÍ Pharmaceuticals is an EU-GMP European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal, and distributing EU GMP-certified cannabinoid-containing pharmaceuticals globally. SOMAÍ emphasizes scientific pharmacology applications with EU-GMP standards to effectively and consistently deliver treatments to the endocannabinoid system across all markets.

SOMAÍ Pharmaceuticals Management

Leadership team at SOMAÍ Pharmaceuticals

Chief Operating Officer and Co-Founder

George Bellow

Founder, Chairman and CEO

Michael Sassano

Locked Features

Join now and verify your accreditation status to gain access to:

  • SOMAÍ Pharmaceuticals current valuation
  • SOMAÍ Pharmaceuticals stock price
  • Available deals in SOMAÍ Pharmaceuticals and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in SOMAÍ Pharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like SOMAÍ Pharmaceuticals through EquityZen funds. These investments are made available by existing SOMAÍ Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell SOMAÍ Pharmaceuticals stock?

Shareholders can sell their SOMAÍ Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."